📄
SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases.
active
paper
Created:
By: unknown
Quality:
50%
✓ SciDEX
ID: paper-22817743
📄 Paper Details
SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases.
["Oltean S", "Gammons M", "Hulse R", "Hamdollah-Zadeh M", "Mavrou A", "Donaldson L", "Salmon A", "Harper S", "Ladomery M", "Bates D"]
Abstract
SRPK1 (serine-arginine protein kinase 1) is a protein kinase that specifically phosphorylates proteins containing serine-arginine-rich domains. Its substrates include a family of SR proteins that are key regulators of mRNA AS (alternative splicing). VEGF (vascular endothelial growth factor), a principal angiogenesis factor contains an alternative 3' splice site in the terminal exon that defines a family of isoforms with a different amino acid sequence at the C-terminal end, resulting in anti-ang...
▸Metadata
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
5%
Debates
0
Incoming
1
Outgoing
1
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.